New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 30, 2014
11:24 EDTMNKDMannKind climbs, retraces parabolic intraday gains
The stock has been on a parabolic rise today and after peaking at $9.46, a new 52-week high and multi-year high, has begun to retrace. At the current price of $9.07, next support is at $8.90. On a very long term chart, price movement has the appearance of a volatile rounding bottom, which is bullish for price, with the $10 area as major resistance.
News For MNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
11:47 EDTMNKDMannKind's Afrezza lags behind in inhaled insulin market, The Street reports
The number of prescriptions written for MannKind's (MNKD) Afrezza is lagging behind in the diabetes market, reports The Street. This comes five months after Sanofi (SNY) launched the product. Afrezza is also under-performing Exubera, the first inhaled insulin launched by Pfizer (PFE) nine years ago. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use